A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours
NCT02182128
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Tumors
Interventions
DRUG:
BIBF 1120
Sponsor
Boehringer Ingelheim